Back

The effect of high-flow and low-flow conditions on left atrial thrombotic risk: a porcine model of mitral valve regurgitation and lone atrial fibrillation

12 April 2026 (08:00 - 18:30)
Organised by: Logo
Congress Presentation Part of: Poster session (1): supraventricular arrhythmias Arrhythmias EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Sven Van Laer

Antwerp University Hospital, Edegem (Belgium)

196 More presentations in this session

Presentation thumbnail
Electrocardiographic differentiation of narrow QRS complex tachycardia: validation of the new aVL and aVR criteria and a unifying approach to ECG analysis
Doctor J. Stec (Cracow, PL)
Abstract Slides Video
Presentation thumbnail
Characterization of paroxysmal atrial fibrillation in atrial septal defects: contribution of a left atrial substrate
Doctor N. Ramdat Misier (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Spatial distribution of effective refractory period in atrial fibrillation patients
Associate Professor A. Loewe (Karlsruhe, DE)
Abstract Slides
Presentation thumbnail
Early onset atrial fibrillation as a marker of inherited cardiomyopathy: lessons from combined imaging and genetic assessment
Doctor V. Rella (Milan, IT)
Abstract Slides Video
Presentation thumbnail
BMI discrepancy and new-onset atrial fibrillation: findings from UK biobank
Doctor J. Choi (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session (1): supraventricular arrhythmias

The Event

Event poster

EHRA 2026

12 April 2026 08:00 CET
You may be interested in
thumbnail
Congress Presentation
The effect of tachypacing induced atrial fibrillation on atrial thrombotic biomarkers in a porcine model
thumbnail
Congress Presentation
The effect of short-term mitral valve regurgitation on atrial remodelling and atrial fibrillation inducibility in an experimental porcine model
thumbnail
Congress Presentation
Incidence of left atrial thrombi in patients with atrial fibrillation and low thromboembolic risk: do we always need transesophageal echocardiography before rhythm control therapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources